Achieved YUTREPIA® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarterMore than 3,600 unique prescriptions received and 2,900 patients treated to date ...

AUSTIN, TX / ACCESS Newswire / March 2, 2026 / In modern metabolic medicine, few treatments have reshaped care like GLP-1 receptor agonists. If you are asking what is semaglutide, it is a prescription ...

George Weston Limited (TSX: WN) (“GWL” or the “Company”) today announced its consolidated unaudited results for the 13 weeks ended December 31, 2025(2).

Tevogen ('Tevogen Bio Holdings Inc.” or 'Company”) (Nasdaq: TVGN) today announced that its Board of Directors (the 'Board”) ...

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, ...

NeuroPace, Inc. ( NPCE) Q4 2025 Earnings Call March 3, 2026 4:30 PM EST Good afternoon, and welcome to NeuroPace Fourth Quarter 2025 Conference Call. As a reminder, this call is being recorded.

Phosphate Mining, Beneficiation, Mine Waste Valorization, Circular Economy, Sustainability, Jordan Share and Cite: Titi, A.

National Vision Holdings, Inc. Reports Fourth Quarter and Fiscal 2025 Financial ResultsThe Associated PressDULUTH, Ga. DULUTH, Ga.–(BUSINESS WIRE)–Mar 4, 2026– National Vision Holdings, Inc. (NASDAQ: ...

Q4 2025 revenues of $112M, +46% vs. Q4 2024Furoscix® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza® Q4 2025 net sales of $23M, +25% vs. Q4 ...

As of March 2026, TestoPrime is available in over 130 countries and holds the Clinicians' Choice medical accreditation as ...

Introduction Intensive care unit (ICU) visiting restrictions in hospitals, implemented due to infection control and other factors, limited contact between patients and family members, affecting ...

With us today, we have Community Health. On the stage is Kevin Hammons, CEO; and Jason Johnson, CFO. Thanks, Rishi. And first, let me say thanks for hosting us today and for everyone joining us. As I ...